In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab ® ) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
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Introduction
Chronic lymphocytic leukemia (CLL) is an incurable disease with a median age at the time of diagnosis between 65 and 70 years and with about 22-30% of patients younger than 60 years [1, 3] . The variable clinical course of the disease is strongly influenced by different 0145-2126/$ -see front matter © 2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.leukres.2013. 11.009 biologic markers that do not appear to differ substantially according to age at diagnosis [4] [5] [6] [7] [8] . However, Dohner et al. observed that the presence of deletion 11q was a profound stratifier of survival in patients aged <55 years, but not in patients aged >55 years [9] , while in all age patients 17p deletion and/or TP53 mutations are well known poor prognostic markers [10] [11] [12] . It has been estimated that 60% of patients ≤55 years require treatment and that the life expectancy of younger CLL patients is significantly shorter than that of the age-matched general population [2, 3] . A significant clinical improvement in the outcome of CLL patients has been obtained by the combination of the anti-CD20 monoclonal antibody rituximab with fludarabine-based regimens, in particular, the fludarabine and cyclophosphamide regimen (FCR) [13, 14] .
Campath (Alemtuzumab ® ) a chimeric anti-CD52 monoclonal antibody is effective in the management of CLL and has shown activity regardless of the genetic risk groups [15] [16] [17] [18] . Results from a single-group phase 2 study by Elter et al. suggested that the fludarabine and alemtuzumab (FA) combination could improve the outcome of patients with relapsed or refractory CLL [19] . The same authors confirmed the efficacy of the FA combination in a study where this regimen was compared with fludarabine monotherapy in patients with relapsed or refractory CLL [20] .
In order to prolong the response duration, a post-remissional treatment with alemtuzumab [21, 22] and, in younger and physically fit patients with poor prognosis, the role of a stem cell transplant (SCT) [23] [24] [25] [26] have also been explored.
The GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) promoted a prospective multicenter phase II trial to evaluate in CLL patients younger than 60 years the efficacy and safety of a treatment approach with the FA regimen.
Design and methods

Study design
A prospective, multicenter, phase II trial was designed for young CLL, with adverse biologic characteristics requiring front-line therapy. The primary objectives of the study were to define the overall response (OR) and complete response (CR) rates after FA regimen. The secondary objectives were to assess the toxicity, the progression-free survival (PFS), the overall survival (OS), the relationship between the baseline clinical and biologic features and the outcome of the patients.
Inclusion and exclusion criteria
Inclusion criteria were age ≤60 years, no prior treatment, advanced Binet stage (C) or less advanced stage (B or A) [27] with clinical signs of active disease according to the NCI-WG criteria [28] and a "high risk" (HR) biologic profile. For the purpose of this study, a HR biologic profile was defined by the presence of: (1), deletion 17p (≥20%; HRa subset); or (2) deletion 11q with ≥1 additional unfavorable factor (germline IGHV status, ZAP-70 and/or CD38 expression; HRb subset); or (3) germline IGHV or mutated VH3-21 and ≥2 unfavorable factors (ZAP-70 and/or CD38 expression, trisomy 12; deletion 6q; HRc subset).
Institutional ethic committees approved the study. Patients signed a written informed consent. The EudraCT number registration of the study is 2005-002476-15.
Study treatment
Patients received 4 monthly courses of the FA regimen (fludarabine, 30 mg/m2 iv; alemtuzumab, 30 mg iv, days 1-3) [19, 20] . Responding patients with no evidence of residual disease at the molecular level (mol-CR) underwent a peripheral blood stem cell (PBSC) mobilization only, while patients with residual disease (partial response, PR; complete response, CR; cytometric complete response, cy-CR) underwent post-remissional therapy. In order of priority, 3 post-remissional treatment options were considered: a reduced intensity allogeneic PB SCT or, in the absence of a sibling donor, an autologous PB SCT or, in the absence of a sufficient harvest, treatment with alemtuzumab sc, 30 mg weekly for a maximum of 12 weeks (Supplementary Table 1) .
Supplementary material related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.leukres. 2013.11.009.
Supportive treatment
All patients received bactrim and high dose valacyclovir prophylaxis (2 g/8 h) with weekly CMV antigenemia monitoring. Treatment was stopped in the presence of life-threatening adverse events, persistent (≥4 weeks) grade ≥2 cytopenia, infection or other toxicity.
Efficacy assessments
Response was defined between the 8 • and the 12 • week from the last fludarabine and alemtuzumab administration. Response was assessed according to the 1996 NCI-WG guidelines [28] and CR was confirmed in all cases by bone marrow biopsy.
In addition, in all CR patients, computed tomography (CT) scans were used. In patients with imaging confirmed CR, a centralized evaluation of the minimal residual disease (MRD) was performed both on PB and bone marrow (BM) by four color flow cytometry. In patients with no evidence of cytometric residual disease, molecular response was also assessed by polymerase chain reaction (PCR). In a subset of patients a gene expression profile analysis (GEP) was performed as previously described [29] Statistical analysis Differences in the distributions of prognostic factors were analyzed by the 2 or Fisher's exact test and by the Kruskal-Wallis test. The probability of survival was estimated using the Kaplan-Meier method. The log-rank test was used to compare the effect of treatment and risk factor categories, while confidence intervals were estimated (95% CIs) using the Simon and Lee method. Logistic regression and Cox proportional hazard regression models were performed to examine risk factors affecting treatment response and survival outcomes. To ascertain the pure impact of the FA regimen and the prognostic effect of baseline clinical and biologic variables patients who underwent SCT were censored at the time of transplant.
Results
Study population
Between December 2005 and February 2009, the biologic profile of 86 consecutive young patients with CLL and a progressive disease was assessed. Forty-five patients (52%) showed a HR biologic profile and were treated with the FA regimen. The clinical and biologic characteristics of the patients are reported in Table 1 . The distribution of the three subsets of HR patients was: 26.7% for the group of patients with deletion 17p (HRa subset), 40% for the group including patients with deletion 11q and 1 or more additional adverse biologic factors (HRb subset), and 33.3% for the group represented by cases with unmutated IGHV and 2 or more additional adverse biologic factors (HRc subset). 
Response to FA regimen
The majority of patients (89%) completed the planned 4 courses of FA treatment.
Two patients withdrew from treatment because of severe reaction during the first alemtuzumab infusion. On an intentionto-treat basis, 34 HR patients (75.5%) responded to FA regimen with 11 (24.4%) CRs and 23 (51.1%) PRs (Table 2 ). Out of the 11 patients who achieved a CR, 8 (18%) showed no residual disease at the cytometric level (cy-CR) and 5 both at the cytometric and molecular level (mol-CR). A treatment failure was recorded in 9 cases (stable disease, 5; progressive disease, 4).
The effect of the clinical and biologic variables on response is detailed in Table 2 . Patients with deletion 17p or 11q showed the lowest CR rates (HRa vs HRb vs HRc subset, 8.3% vs 16.7% vs 46.7%; p = .07). The proportion of patients who obtained a CR was significantly lower in the presence of a short interval from CLL diagnosis, ≤12 months (p = .006), increased ␤2M levels (p = .02). At multivariate analysis, the interval between CLL diagnosis and treatment (p = .02), increased ␤2M (p < .027) and deletion 17p (p < .043) maintained a significant and independent effect on the achievement of CR.
GEP analysis revealed a distinctive signature associated with response to treatment with 357 differentially expressed probesets, the majority being downregulated in patients who did not obtain a CR (Fig. 1A) .
Furthermore, DAVID functional annotation analysis evidenced in patients who failed to reach a CR an overrepresentation, of genes involved in translation, proteasomal catabolic processes, RNA splicing, Ras signaling, cellular response to stress, DNA repair and B cell activation (Fig. 1B) .
In addition, in the cases who did not achieve a CR a significant downmodulation (p = .014) of the transcript encoding for the CD52 antigen was observed.
Out of the 29 patients who achieved a response with FA and showed the evidence of residual disease, 14 underwent SCT and all are alive (median time from SCT, 40 months). However, while the 6 patients who had an allogeneic SCT are in persistent CR (2 in mol-CR), 4 out of the 8 who had an autologous SCT have relapsed after a median time of 29 months. Patients subgroups: HRa includes, patients with deletion 17p (≥20%); HRb, patients with deletion 11q and 1 or more additional adverse biologic factors; HRc, IGHV unmutated patients with 2 or more additional adverse biologic factors.
Survival
The 3-year PFS and OS are 42.5% (95%CI: 27.4-65.9) and 79.9% (95%CI: 66.6-95.9), respectively. Baseline clinical and biologic parameters associated with a significantly higher PFS after FluCam were a longer interval from CLL diagnosis (p = .0007), the absence of bulky nodes (p = .02), or increased ␤2M levels (p = .05). Patients with deletion 17p or 11q showed a shorter, though not significantly inferior PFS (PFS at 3 years, 17p-, 51% vs 11q-, 28%, vs no deletion 17p or 11q, 60%; p = .85; Fig. 2) . At multivariate analysis, the significant and independent baseline factors influencing PFS were the interval from CLL diagnosis (p = .012; HR: 3.2; 95% CI: 1.2-8.4) and the presence of bulky nodes (p = .016; HR: 0.31; 95% CI: 0.12-0.77). A significantly longer PFS was observed in patients who achieved a CR (PFS at 3 years, CR vs PR, 80.0% vs 12.7%; p = .03) and in patients who after response to FA underwent an allogeneic or autologous SCT as compared to patients who did not receive further treatment (p < .02; HR: 0.30; 95% CI: 0.11-0.84). Baseline variables with a significant effect on survival probability were the age of patients (p = .04), the interval from CLL diagnosis (p = .01), and the LDH value. Patients with deletion 17p showed the lowest OS probability (OS at 3 years, deletion 17p vs deletion 11q vs trisomy 12 or deletion 13q, or no abnormalities, 69% vs 85% vs 83%). However, the difference did not reach statistical significance (p = .22), presumably because of the limited sample size (Fig. 2) . 
Safety
A grade III-IV granulocytopenia was recorded after 18% of courses and in 38% of patients. However, a severe infection was recorded in a lower proportion of patients, 13%. Three patients (6.7%) experienced a CMV reactivation that responded to ganciclovir iv, while no case of symptomatic CMV infection was observed. Alemtuzumab-related grade 3-4 adverse infusion reactions were recorded in 2 patients (4.4%) who discontinued treatment. During the follow-up, a second malignancy was recorded in 2 cases (prostate carcinoma, Kaposi sarcoma) and 1 patient developed a Richter's syndrome. Seven patients have died (15.5%). The cause of death was an infection in 1 patient and disease progression in 6 (CLL, 5 cases, Richter's syndrome, 1).
Discussion
We know today a large number of genetic abnormalities associated with the pathogenesis and prognosis of CLL [30] [31] [32] [33] . At the time this study was designed, in the pre-FCR era, there was evidence that both deletions 17p and 11q were associated with a poor outcome after treatment, and a treatment strategy including fludarabine combined with the monoclonal antibody alemtuzumab was judged as an appropriate first line treatment approach for young CLL patients with an overall poor prognostic likelihood.
About half of the younger patients we analyzed at the time of first-line treatment showed an adverse biologic profile. On an intention-to-treat basis, a response was obtained after FA by 75.5% of these patients with a CR rate of 24.4%, including 18% of cytometric CRs and a sizable number of molecular CRs. A shorter interval from diagnosis and beta2-microglobulin, were significantly associated with an adverse outcome. The genetic profile identified a different pattern of response to FA regimen. Patients with unmutated IGHV and no deletion 11q or 17p showed the best response in terms of OR, 80%, and CR, 47%, rates while patients with deletion 11q showed a very low CR rate, 17%, and patients harboring a deletion 17p the worse response in terms of both, OR, 58% and CR, 8%, rates.
Interestingly, GEP analysis revealed a significant downmodulation of transcripts involved in the DNA repair and/or apoptosis regulation and a significant downmodulation of the transcript encoding for the CD52 antigen in patients who obtained only a PR or no response. If we consider the results of the CLL8 study [14] , with the FCR regimen, being today the gold standard front-line therapy for fit patients with CLL, patients with unmutated IGHV and no deletion 11q or 17p showed a similar CR rate after FA. Unfortunately, patients with deletion 17p did not show a better response rate with FA, and patients with deletion 11q revealed a very unsatisfactory CR rate and they appear to respond better to the FCR regimen. This finding further suggests that treatment combinations including rituximab and alkylating agents such as cyclophosphamide or bendamustine are more effective in patients with the 11q deletion [34, 35] .
Even though the analysis of a small cohort of 45 patients should be consider as exploratory and no conclusions can be drawn, it is worth noting that the introduction of a post-remissional allogeneic or autologous SCT showed a benefit in prolonging response after treatment. This observation is in line with that of two studies that reported a benefit in the outcome of CLL patients when the SCT was performed in an early phase of the disease [25, 26] .
The safety profile of FA was acceptable. Infections were less frequent than expected considering the immunodepressive effect of both agents. The low cumulative dose of alemtuzumab, the extended prophylaxis and the absence of prior treatments played a favorable effect in restraining infections. Interestingly, on high dose valacyclovir prophylaxis, no CMV symptomatic infections were observed and a relatively low proportion of patients developed a CMV reactivation.
In conclusion, in this study about half of young CLL patients requiring therapy showed adverse biologic features. In this subset of patients FA regimen given as front-line treatment revealed a manageable safety profile and provided evidence of a patient benefit. Further confirmatory phase III studies in larger series of patients comparing FA with the gold standard regimen for CLL and an extended follow-up to evaluate survival end points and longterm toxicity are required. Vergata, Rome, Italy; Giovanni Del Poeta, Hematology, Ospedale S. Eugenio, Rome, Italy; Sergio Storti, Istituto di EmatologiaCampobasso, Italy; Nicola Di Renzo, Divisione di Ematologia, Lecce, Italy.
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